A New Drug Delivery System for Liver Cancer
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy
This project is creating a new way to deliver two powerful drugs together to fight liver cancer, especially focusing on cells that make the cancer resistant to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11124644 on NIH RePORTER |
What this research studies
Liver cancer is becoming more common, and current treatments often face challenges like drug resistance and cancer coming back. This project aims to overcome these issues by developing a special delivery system called polymeric micelles. These micelles are designed to carry two different drugs: cyclopamine, which targets cancer stem cells that cause resistance, and paclitaxel, a chemotherapy drug that stops cancer cells from growing. By delivering both drugs at once, the goal is to more effectively eliminate both resistant cancer stem cells and other growing cancer cells.
Who could benefit from this research
Good fit: Patients with hepatocellular carcinoma (HCC) who face challenges with current chemotherapy options or experience cancer recurrence might be interested in future developments from this research.
Not a fit: Patients without hepatocellular carcinoma would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this approach could offer a more effective treatment option for hepatocellular carcinoma, potentially overcoming drug resistance and reducing cancer recurrence.
How similar studies have performed: This approach combines known drugs with a novel delivery system and dual-targeting strategy, building on preliminary studies that showed promise.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Li, Chun — University of Tx Md Anderson Can Ctr
- Study coordinator: Li, Chun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.